中东、北非 (MENA) 的生命科学产业的展望、预测 (～2020年)
Middle East and North Africa (MENA) Life Sciences Industry Outlook, Forecast to 2020
|出版商||Frost & Sullivan||商品编码||910105|
|出版日期||内容资讯||英文 42 Pages
|中东、北非 (MENA) 的生命科学产业的展望、预测 (～2020年) Middle East and North Africa (MENA) Life Sciences Industry Outlook, Forecast to 2020|
|出版日期: 2019年08月23日||内容资讯: 英文 42 Pages||
现场制造的扩大及对文明病的政府支出的增加，预计成为2020年主要的市场成长的推动要素。中东、北非 (MENA) 的生命科学市场规模，预计至2020年超过400亿美元。
本报告提供中东、北非 (MENA) 的生命科学产业的相关调查，市场概要与预测，收益预测，各市场区隔的预测，主要趋势与成长机会，策略性建议和未来展望等相关汇整。
Increased Local Manufacturing and Government Spending on Lifestyle Diseases to be Key Driving Factors in 2020
In this research deliverable, Frost & Sullivan's analyst team provides bold perspectives and predictions for the Middle East and North Africa (MENA) region's life sciences industry in 2020. The markets covered include pharmaceuticals, biotechnology, and in-vitro diagnostics. The analysis captures the impact of trends that are expected to transpire over 2019 and 2020 as organizations prepare for the future. This study provides guidance on where to find the greatest opportunities for expansion and which key companies to look out for.
Frost & Sullivan projects the MENA Life Sciences market to cross US$ 40 billion by 2020. A shift in the focus of healthcare towards lifestyle-driven chronic health conditions and an increasingly affluent population's preference for research-based branded drugs and preventive screening diagnostic tests are expected to drive the MENA life sciences market during the forecast period (2019 to 2020). Ongoing economic diversification and localization efforts by governments will make the domestic production of branded generic drugs more important than ever for both local consumption and export services. In addition, the regulatory environment will see a major transformation in each country. Given the on-going localization trends, it will be critical for global pharma MNCs to strategically collaborate with local agents or CMOs for their expertise on domestic contacts, customs regulations, and faster time to market in the MENA region. Areas exhibiting high growth opportunities will be the main focus of governments and industries alike. Business models specific to MENA will be pursued in contrast to those in larger markets of developed nations. Mergers and acquisitions are expected as stakeholders collaborate to achieve common outcomes. The outlook foresees increased collaboration and M&A activities between the life sciences and other healthcare sectors, in which preventative digital technology innovations will support the prevention of the onset of chronic and genetic diseases. Health spending is expected to rise in the region with governments aiming to meet sustainable development goals.